Tianjin Med J ›› 2018, Vol. 46 ›› Issue (8): 794-798.doi: 10.11958/20180561

Previous Articles     Next Articles

Etiology and treatment strategies of anemia in myelodysplastic syndromes

HAN Bing, LI Hong-min, CHEN Fang-fei, WU Jie   

  1. Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China
  • Received:2018-04-09 Revised:2018-07-17 Published:2018-08-15 Online:2018-08-23

Abstract: Myelodysplastic syndrome (MDS) is a group of highly heterogeneous diseases. Anemia is the most common manifestation of MDS, which is also an important factor affecting the survival and quality of life in MDS patients. Different factors are involved in the pathogenesis of anemia of MDS, and for a particular patient, anemia maybe the results of multiple factors. In current review, we summarized the common reasons for MDS anemia including expansion of abnormal clone, immune regulation dysfunction, abnormal hematopoiesis concerning with 5q-, ineffective hematopoiesis and iron overload. Erythropoietin (EPO), immunosuppressive agent, iron chelators, immunomodulatory, transforming growth factor beta (TGF- β) pathway inhibitor, demethylation drugs and hematopoiesis stem cell transplantation may help to improve the anemia of different causes in MDS patients.

Key words: myelodysplastic syndromes, anemia, cause of disease, origin of a disease